Table 2 Association between measures obtained by 2DE-ST before anthracycline, before trastuzumab and after 3 months trastuzumab, and CMR-LVEF at 6 months
2DE | CMR-LVEF at 6 months after start trastuzumab | Change in CMR-LVEF at 6 months after start trastuzumab | Cardiotoxicitya | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariable analysis | Multivariable analysis | Univariable | Univariable | |||||||||||
Mean difference (95% CI) | P-value | R2 | Mean difference (95% CI) | P-value | R2 | Mean difference (95% CI) | P-value | R2 | Median in patients with CTOX [IQR] | median in patients without CTOX [IQR] | OR (95% CI) | P-value | R2 | |
Before start anthracycline | ||||||||||||||
 LVEF, % | 0.42 (−0.02, 0.85) | 0.058 | 0.11 |  |  |  | 0.23 (− 0.22, 0.68) | 0.297 | 0.04 | 63.0 [58.8, 65.5] | 69.0 [64.0, 77.0] | 0.77 (0.61, 0.97) | 0.027 | 0.26 |
 ST-GLS, % | 0.24 (−0.83, 1.31) | 0.649 | 0.01 |  |  |  | 0.42 (− 0.64, 1.49) | 0.422 | 0.02 | −17.0 [− 18.5, − 14.6] | − 16.0 [− 18.5, − 13.0] | 0.81 (0.59, 1.11) | 0.377 | 0.05 |
 ST-GRS, % | 0.11 (− 0.11, 0.33) | 0.322 | 0.01 |  |  |  | − 0.03 (− 0.26, 0.19) | 0.767 | 0.09 | 26.5 [15.2, 36.0] | 27.2 [13.4, 36.5] | 0.99 (0.93, 1.05) | 0.721 | 0.01 |
Change during anthracycline | ||||||||||||||
 LVEF, % | 0.11 (− 0.29, 0.51) | 0.570 | 0.01 | 0.03 (− 0.39, 0.45) | 0.879 | 0.07 | −0.05 (− 0.45, 0.35) | 0.790 | 0.01 | −2.0 [−7.0, 1.0] | −7.0 [− 13.0, 0.0] | 1.07 (0.95, 1.21) | 0.250 | 0.05 |
 ST-GLS, % | − 0.86 (− 2.02, 0.30) | 0.142 | 0.07 | − 0.83 (− 2.08, 0.42) | 0.186 |  | −0.86 (−2.03, 0.30) | 0.141 | 0.07 | 4.4 [0.0, 6.0] | 0.2 [−0.1, 2.0] | 1.39 (0.99, 1.95) | 0.058 | 0.12 |
 ST-GRS, % | −0.04 (− 0.39, 0.31) | 0.829 | 0.00 |  |  |  | 0.08 (− 0.27, 0.43) | 0.631 | 0.01 | −4.2 [− 14.0, 2.3] | −0.9 [− 12.2, 4.3] | 1.00 (0.92, 1.10) | 0.942 | 0.00 |
Before start trastuzumab | ||||||||||||||
 LVEF, % | 0.85 (0.42, 1.27) | < 0.001 | 0.30 | 0.87 (0.41, 1.34) | < 0.001 | 0.30 | 0.32 (− 0.16, 0.80) | 0.189 | 0.05 | 60.0 [57.3, 62.8] | 63.0 [60.0, 66.0] | 0.88 (0.75, 1.02) | 0.080 | 0.13 |
 ST-GLS, % | − 0.42 (− 1.31, 0.46) | 0.337 | 0.03 | 0.14 (− 0.68, 0.95) | 0.738 |  | −0.28 (− 1.14, 0.58) | 0.519 | 0.01 | −13.7 [− 16.9, − 11.2] | − 15.0 [− 17.3, − 12.2] | 1.13 (0.87, 1.46) | 0.365 | 0.03 |
 ST-GRS, % | 0.08 (− 0.13, 0.28) | 0.464 | 0.07 |  |  |  | −0.02 (− 0.22, 0.18) | 0.831 | 0.00 | 31.4 [4.5, 42.1] | 22.4 [8.5, 35.5] | 0.99 (0.94, 1.05) | 0.830 | 0.00 |
3 Months after start trastuzumab | ||||||||||||||
 LVEF, % | 0.59 (0.30, 0.88) | < 0.001 | 0.32 | 0.56 (0.24, 0.87) | 0.001 | 0.35 | 0.29 (− 0.04, 0.61) | 0.080 | 0.08 | 55.0 [43.4, 62.8] | 60.0 [57.0, 63.0] | 0.85 (0.74, 0.98) | 0.029 | 0.28 |
 ST-GLS, % | − 1.14 (− 2.07, − 0.19) | 0.018 | 0.10 | − 0.46 (− 1.34, 0.41) | 0.288 |  | −0.62 (− 1.54, 0.30) | 0.179 | 0.05 | −11.6 [− 15.3, − 9.4] | − 14.1 [− 16.6, − 11.7] | 1.36 (0.94, 1.84) | 0.073 | 0.13 |
 ST-GRS, % | 0.04 (− 0.23, 0.31) | 0.751 | 0.00 |  |  |  | −0.15 (− 0.40, 0.10) | 0.237 | 0.04 | 28.1 [8.5, 35.3] | 21.2 [12.1, 32.0] | 1.03 (0.95, 1.11) | 0.532 | 0.02 |
Change at 3 months after start trastuzumab | ||||||||||||||
 LVEF, % | 0.30 (−0.11, − 0.71) | 0.144 | 0.06 | 0.33 (− 0.06, 0.72) | 0.094 | 0.22 | 0.21 (−0.19, 0.61) | 0.292 | 0.03 | −11.0 [− 19.0, − 2.0] | − 4.0 [− 7.0, 0.0] | 0.90 (0.80, 1.01) | 0.079 | 0.09 |
 ST-GLS, % | − 1.17 (− 2.14, − 0.20) | 0.019 | 0.14 | −1.20 (− 2.16, − 0.24) | 0.016 |  | −1.10 (−2.02, − 0.18) | 0.021 | 0.14 | 5.2 [2.8, 7.0] | 1.7 [−0.2, 3.0] | 1.81 (1.11, 2.93) | 0.016 | 0.34 |
 ST-GRS, % | − 0.17 (− 0.57, 0.23) | 0.386 | 0.03 |  |  |  | −0.12 (− 0.52, 0.27) | 0.521 | 0.02 | −0.7 [− 10.0, 2.0] | −3.0 [− 9.7, 1.4] | 1.03 (0.92, 1.15) | 0.610 | 0.01 |